Drug Profile
Research programme: inflammation therapeutics - VBL Therapeutics
Alternative Names: VB-202; VB-302; VB-703Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator Vascular Biogenics
- Developer VBL Therapeutics
- Class Antifibrotics; Hepatoprotectants; Phospholipids; Small molecules
- Mechanism of Action CD14 antigen inhibitors; Cell movement inhibitors; Cytokine inhibitors; Interleukin 12 subunit p40 inhibitors; Phospholipid modulators; Toll like receptor 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Atherosclerosis; Multiple sclerosis; Non-alcoholic steatohepatitis; Renal fibrosis; Rheumatoid arthritis
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in Israel (PO)
- 28 Jul 2023 No recent reports of development identified for preclinical development in Renal-fibrosis in Israel (PO)
- 07 Jul 2021 Preclinical development is ongoing for Non-alcoholic steatohepatitis and Renal fibrosis in Israel (VBL Therapeutics pipeline, July 2021)